PT  - JOURNAL ARTICLE
AU  - Emily Hinchcliff
AU  - Shannon Neville Westin
AU  - Graziela Dal Molin
AU  - Christopher J LaFargue
AU  - Robert L. Coleman
TI  - Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
AID  - 10.1136/ijgc-2019-000499
DP  - 2019 Jun 01
TA  - International Journal of Gynecologic Cancer
PG  - 956--968
VI  - 29
IP  - 5
4099  - http://ijgc.bmj.com/content/29/5/956.short
4100  - http://ijgc.bmj.com/content/29/5/956.full
SO  - Int J Gynecol Cancer2019 Jun 01; 29
AB  - The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key evidence for their use and therapeutic indications. Furthermore, we provide an overview of the development of PARPi resistance and the emerging role of PARPi combination therapies, including those with anti-angiogenic and immunotherapeutic agents.